CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Translating Engineered AAV Capsids Into Manufacturable Gene Therapies

  Engineered AAV capsids offer improved targeting and efficiency but introduce manufacturing, analytical, immunogenicity, and regulatory complexities requiring early, integrated development strategies.

• Navigating CMC Regulation For Plasmid DNA In Gene Therapy

  Explore how evolving regulatory pathways and CMC innovation are shaping the future of gene therapy and viral vector production, plus what to consider when selecting a CDMO partner.

• Improving Formulation And Aliquoting Efficiency With Mixing Solutions

  Separate formulation, filtration and aliquoting add transfers and integrity tests. A single closed flowpath can improve time, yield and contamination control.

• 9 Logistics And Distribution Recommendations For CGTs

  Cell and gene therapy commercialization requires tailored logistics strategies. Explore nine recommendations covering site readiness, reimbursement gaps, packaging, testing, and coordination.

• Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors

  Progress in gene therapy manufacturing is being driven by improved cell line performance and scalable bioprocessing. See how high-density growth helps streamline development to larger-scale production.

• Automated Manufacturing Of CD34-Enriched Cell Products

  See how this streamlined approach produces high-quality CD34+ cell products from cryopreserved apheresis material, integrating thawing, washing, and enrichment into a single automated workflow.

• Rapid Walkaway Solution For Assessing Viability In Cancer Organoids

  Assess anti-cancer compounds' effects on organoid size and morphology with colorectal cancer organoids as well as discover automated imaging and viability assays to streamline drug screening and aid early identification.

• Phase 1 Clinical Trial Designs And Strategies

  With tailored guidance, sponsors can align their modern model-based and model-assisted design choices to program goals, accelerating progress while safeguarding patients.

• Selecting A Central Lab Network For Radiopharmaceutical Readiness

  A wave of late-stage radiopharmaceutical trials is straining lab infrastructure concentrated in a handful of academic centers, limiting site diversity, expertise, and trial capacity nationwide.

• A Human-Relevant Model Of The Liver Sinusoid

  This organ-on-a-chip model minimizes drug absorption while maintaining the essential architecture. Explore the specifications of this product engineered to model the human liver.